Pharmaceutical Products tenders (CPV 33600000)

Project title: NHS National Framework for Ferric Carboxymaltose Injection Offer reference number: CM/TNS/26/5743 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to a maximum of 24 months. CM/TNS/26/5743 Ferric Carboxymaltose Injection Lot 1 CESW 01/03/2027 to 31/01/2029 (23 months) Lot 2 NWLN 01/03/2027 to 31/05/2028 (15 months) Lot 3 LSNE 01/03/2027 to 31/05/2028 (15 months) Published By: Medicines Procurement and Supply Chain - NHS Medicines Value & Access, NHS England

Project title: NHS Midlands & East Framework for Denosumab 60mg PFS Offer reference number: CM/TNS/26/5768 Period of framework: 01 January 2027 to 31 August 2027 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 16 months. Published By: Medicines Procurement and Supply Chain - NHS Medicines Value & Access, NHS England

NHS National Framework for Generics Orals, Non-Parenteral & Housekeeping Offer Reference number: CM/PHG/25/5738 Period of framework agreement: Dates detailed below, with an option or options to extend (at the authority’s discretion) for a period or periods up to a total of 48 months. Potential periods of call-offs under the framework agreement: CM/PHG/25/5738/01 - Oral & Non-Parenteral Products: CESW (Central/Midlands and Southwest): 1st June 2027 to 31st May 2030 (36 months) LSNE (London South and Northeast 1st June 2027 to 31st May 2030 (36 months) NWLN (Northwest and London North): 1st June…

Project title: NHS National Framework for Lenvatinib Offer reference number: CM/TNS/26/5751 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to a maximum of 24 months. CM/TNS/26/5751 Lenvatinib Lot 1 CESW: 01/06/2027 to 31/01/2029 (20 months) Lot 2 NWLN: 01/06/2027 to 30/09/2028 (16 months) Lot 3 LSNE: 01/06/2027 to 31/05/2028 (12 months) Published By: Medicines Procurement and Supply Chain - NHS Medicines Value & Access, NHS England

Suffolk County Council (Public Health, Communities and Public Safety) are currently out to tender for the postal supply of Nicotine Replacement Therapy (NRT) and smoking cessation prescription medication. Smoking prevalence in Suffolk is currently estimated at 10.5%. The Council's ambition is to reduce this to 5% or below by 2030. NRT and prescribed smoking cessation medications are recognised as effective interventions to support people to quit smoking and remain an important element of the local stop smoking offer. The Council currently provides access to these products through a…

This tender is for the provision of antiviral medicines for the treatment of Hepatitis C (HCV) to NHS Wales.

Supply of Seasonal Influenza Vaccine.

The North East & Yorkshire NHS Pharmaceutical Purchasing Consortium (NEYPPC) intend to establish a Framework Agreement for the provision of High Tech Homecare Medicines Services. The scope of this procurement will encompass all High Tech Homecare Medicines Services required by member Trusts within the NEY region, while also allowing access for non-member Trusts. Access for non-member Trusts will be available to any publicly funded entity, subject to prior approval from the Authority. The expectation is that the Framework will be multi-award, structured into the following Lots: Lot HT26-A:…

The Common Services Agency (more commonly known as Public Services Delivery Scotland (PSDS)) (‘the authority') acting through its division Procurement, Commissioning and Facilities is undertaking this procurement of supply and delivery of Individual Items and prepacked equipment for single use for people who use drugs including performance and image enhancing drugs as defined in section 5.2 of the IEP guidance IEP-in-Scotland-GPG-SDF-PHS-Oct-2021.pdf​ and for Naloxone products for administering by approved services on behalf of all entities constituted pursuant to the National Health…

The North East and Yorkshire NHS Pharmaceutical Purchasing Consortium intends to establish a framework agreement for the supply of Unlicensed Imported Medicines on behalf of NHS organisations and other eligible public sector bodies. The framework will provide access to a defined range of unlicensed imported medicines, including products requiring over-labelling and translation. These medicines do not hold a UK Marketing Authorisation but are licensed in their country of origin and may be imported and supplied in accordance with Regulation 167 of the Human Medicines Regulations 2012 where a…